BridgeBio Pharma Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.72. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | QDTY | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $46.71 |
52-Week Low | $47.29 | $36.57 |
Enterprise Value | $18.14B | — |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →